五味子乙素下调外泌体纤连蛋白1表达抑制肝细胞癌生长

Schisandrin B downregulates exosomal fibronectin 1 expression to inhibit hepatocellular carcinoma growth.

作者信息Baoyi Jiang, Jie Yang, Qingtian Huang, Wei Li, Qian Peng, Huoye Gan, Tieli Peng, Leyi Yao, Ling Qi
PMID40223922
发布时间2025-03-28
DOI10.3389/fphar.2025.1547685

实验完整度

高

包含体外细胞增殖、凋亡、迁移实验,巨噬细胞共培养系统,外泌体提取与蛋白组学分析,及体内裸鼠移植瘤验证。

主要模型

HepG2细胞系 HCCLM3细胞系 THP-1来源巨噬细胞 BALB/c裸鼠皮下移植瘤模型

重点核对

Sch B浓度:0, 20, 40 μg/mL处理HCC细胞 共培养系统中Sch B处理浓度0, 20, 40 μg/mL 动物实验中Sch B给药剂量:100 mg/kg,灌胃 外泌体提取条件:20 μg/mL Sch B处理48小时

摘要

Introduction: In recent years, natural compounds have attracted wide attention for the treatment of liver cancer due to their therapeutic potential and reduced toxicity. Among these, Schisandrin B (Sch B), a primary bioactive component derived from Schisandra chinensis, has shown notable antitumor activity; however, its specific mechanism remains unclear.Methods: The effect of Sch B on the growth of hepatocellular carcinoma(HCC) cells were assessed using CCK-8 assay, colony formation assay and EdU assay, and apoptosis was detected by flow cytometry. The co-culture system of macrophages and HCC cells was established to detect the effect of Sch B on the cell viability and cell cycle changes of HCC cells in the co-culture system. Then, the migration of HCC cells in the co-culture system was studied using a subtoxic concentration of Sch B. Exosomes of the co-culture system with or without Sch B effect were collected for identification and protein spectrum analysis. The differential protein was analyzed by KEGG enrichment analysis and protein interaction network, which was verified by western blotting. Meanwhile, the expression changes of macrophage polarization markers were detected. Finally, the inhibitory effect of Sch B on HCC and the changes of FN1 were verified by in vivo experiments.Results: Sch B inhibited HCC cell growth; moreover, it significantly suppressed HCC cell proliferation in the co-culture system and induced S-phase cell cycle arrest by downregulating CDK4, CDK2, and cyclin A2 while upregulating p27 Kip1. Additionally, Sch B inhibited the migration of HCC cells in the co-culture system.The differentially expressed protein fibronectin 1(FN1) in liver cancer patients was higher than that in healthy people. Moreover, after SchB treatment, the expression of FN1 protein in exosomes decreased and the macrophages exhibited M1 polarization. In vivo experiments also verified that Sch B inhibited HCC growth and downregulated the expression of FN1 protein in tumor tissues.Conclusion: Sch B may inhibit the development of HCC by inhibiting the expression of exosomal FN1during interactions between macrophages and HCC cells.

实验结论

提炼研究问题、关键发现与证据,快速把握文章的核心贡献。

研究问题
Sch B能否通过影响肿瘤微环境中巨噬细胞与肝癌细胞的相互作用来抑制肝细胞癌生长,其机制是否涉及外泌体及FN1?
核心机制
Sch B通过下调外泌体中纤连蛋白1(FN1)的表达,抑制肝癌细胞增殖和迁移,并可能促进巨噬细胞M1极化。
主要证据
体外共培养实验显示Sch B抑制HCC细胞增殖、迁移并诱导S期阻滞;蛋白组学分析发现FN1下调;体内实验验证Sch B抑制肿瘤生长并降低FN1表达。
研究意义
为天然化合物Sch B在肝癌治疗中的应用提供新的见解。

研究路径

按研究推进顺序梳理实验设计、验证步骤与关键观察。

1

体外评估Sch B对HCC细胞生长的影响

检测Sch B对肝癌细胞增殖、集落形成和凋亡的作用

使用CCK-8、EdU、集落形成实验检测增殖,流式细胞术检测凋亡,处理浓度0、20、40 μg/mL,处理48小时。

2

巨噬细胞与HCC细胞共培养体系中的功能检测

评估Sch B在模拟肿瘤微环境的共培养体系中对HCC细胞增殖、周期和迁移的影响

PMA诱导THP-1分化为巨噬细胞,与HCC细胞共培养,加入Sch B处理,检测细胞活力(CCK-8)、增殖(EdU)、集落形成、细胞周期(流式)及迁移(Transwell),并检测周期蛋白表达。

3

外泌体提取与鉴定

提取并验证共培养体系中的外泌体,为后续蛋白组学分析做准备

收集共培养体系上清,通过超速离心提取外泌体,用Western blot检测标志蛋白Alix、CD9,用TEM观察形态,用纳米粒度仪检测粒径。

4

外泌体蛋白组学分析及差异蛋白验证

寻找Sch B处理后外泌体中差异表达蛋白,并验证FN1的变化

对对照和Sch B处理组外泌体进行蛋白谱分析,筛选差异蛋白,进行KEGG富集和PPI网络分析,用Western blot验证FN1表达,并检测巨噬细胞极化标志物。

5

体内验证Sch B对HCC生长和FN1表达的影响

验证Sch B在体内对肝癌生长的抑制作用及对FN1表达的调控

BALB/c裸鼠皮下接种HCCLM3细胞,建立移植瘤模型,每日灌胃给予100 mg/kg Sch B或溶剂对照,第30天处死,测量肿瘤体积和重量,通过免疫组化、免疫荧光和Western blot检测Ki67和FN1表达。

研究方法

按研究目的归类文中使用的方法,便于定位所需技术。

产品清单

实验环节名称品牌货号
DMEM培养基----
RPMI-1640培养基----
胎牛血清----
佛波酯ACMEC--
五味子乙素SelleckS3600
CCK-8试剂盒GLPBIOCK04
EdU细胞增殖检测试剂盒RIBOBIOC10310
RIPA裂解液SolarbioR0010
BCA蛋白定量试剂盒SolarbioPC0020
PVDF膜----
GAPDH抗体Cell Signaling Technology2118
Alix抗体Cell Signaling Technology2171
β-actin抗体Cell Signaling Technology4970
CDK2抗体Cell Signaling Technology18048
CDK4抗体Cell Signaling Technology12790
cyclin A2抗体Cell Signaling Technology67955
p27 Kip1抗体Cell Signaling Technology3686
CD9抗体Abcamab223052
纤连蛋白1抗体Abcamab268020
Trizol试剂Invitrogen--
HiScript III逆转录预混液Vazyme--
Taq Pro通用SYBR qPCR预混液----
Transwell小室Corning3422
Annexin V-FITC/PI凋亡检测试剂盒ElabscienceE-CK-A211
细胞周期检测试剂盒KeygenKGA512
BALB/c裸鼠GemPharmatech--
Ki67抗体ZSGB-BIOTA800648
FN1抗体Abcamab268020

关键环节

汇总复现实验时建议重点确认的条件及原文阅读提示。

环节核对要点
细胞培养
HCC细胞使用高糖DMEM+10%FBS,THP-1使用RPMI-1640+10%FBS,PMA浓度100 ng/mL处理48小时分化。
阅读提示:STAR methods - Cell culture and drug treatment
药物处理
Sch B粉末用DMSO溶解,储备液稀释1000倍使用,对照组加入等体积DMSO,最终DMSO浓度不超过1/1000。
阅读提示:STAR methods - Cell culture and drug treatment
共培养体系
Transwell上室为PMA处理的THP-1巨噬细胞,下室为HCC细胞,Sch B处理48小时。
阅读提示:STAR methods - Establishment of co-culture system
细胞增殖检测
CCK-8和EdU检测需处理48小时;集落形成实验种板密度800细胞/孔,处理48小时后换新鲜培养基培养14天。
阅读提示:STAR methods - Cell proliferation assay
细胞迁移检测
Transwell迁移实验中上室无FBS,下室含10% FBS,Sch B浓度0, 2.5, 5, 10 μg/mL,培养24小时。
阅读提示:STAR methods - Traswell assay to detect cell migration
外泌体提取
Sch B浓度20 μg/mL处理48小时,外泌体free FBS通过100,000 g离心18小时制备,超速离心条件120,000 g 90分钟。
阅读提示:STAR methods - Exosome extraction and identification
动物实验
每只小鼠皮下注射2×10^6 HCCLM3细胞,给药剂量100 mg/kg Sch B灌胃,每日一次,持续至第30天。
阅读提示:STAR methods - Animal experiment